I like both oncs and ziop on this play, thinking much upside in both. When you hear how, especially here with oncs, words like, with this treatment, can you "less of a dose" due to toxicity with this type drug (previously in other trials)..... to target the cancer using the immunopulse, that sounds like a potential huge winner with me. That tells me that they can use a low low dose and have efficacy without the bad side effects. Surely they test a higher dose, but possibly will not need it for efficacy. Should be a buy and hold here for quite some time....just how much you want to hold, well that depends on you.